Tech Company Financing Transactions

iTeos Therapeutics Funding Round

iTeos Therapeutics closed a $125 million Series B venture capital round on 4/2/2020. Investors included Boxer Capital, RA Capital and 6 Dimensions Capital.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

139 Main St.
Cambridge, MA 02142
USA

Phone

Undisclosed

Website

www.iteostherapeutics.com

Email Address

[email protected]

Overview

iTeos Therapeutics (Nasdaq: ITOS) is a next-generation immuno-oncology company developing innovative anti-cancer agents to fulfil the promise of immunotherapy by targeting the tumor microenvironment to improve the lives of people living with cancer. The Company is targeting two key pathways by which cancer cells suppress the immune system.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Michel Detheux

        

Chief Medical Officer

Joanne Lager

        

Chief Operating Officer

Matthew Call

        

VP - General Counsel

Gregory Sieczkiewicz

        

Browse more venture capital transactions:

Prev: 4/2/2020: Aspen Neuroscience venture capital transaction
Next: 4/2/2020: Pandion Therapeutics venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary